7 results about "Angiotensin-converting enzyme" patented technology

The present disclosure relates to pharmaceutical formulations of angiotensin converting enzyme inhibitor and / or diuretic, particularly stable oral pharmaceutical formulations comprising angiotensin converting enzyme inhibitor and / or diuretic with one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.

Angiotensin-converting enzyme 2 (ACE2) has been identified as a specific receptor for severe acute respiratory syndrome coronavirus (SARS-CoV-1) and several beta-group coronaviruses, including SARS-CoV-2, the causative agent of the recent global pandemic COVID-19, and the low-pathogenic coronavirus HCoV-NL63, a member of the alpha-coronavirus group. The viral spike protein (S) of the viral envelope has been identified as a viral receptor that binds to ACE2 and initiates the viral replication cycle. The present invention provides ACE2 and its mutant or variant forms, as well as viral or non-viral vectors thereof. Methods for treating viral infections in human subjects using such mutant or variant forms are also provided.

The present disclosure relates to pharmaceutical formulations of angiotensin converting enzyme inhibitor and / or diuretic, particularly stable oral pharmaceutical formulations comprising angiotensin converting enzyme inhibitor and / or diuretic with one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.

This invention discloses the application of siRNA in the preparation of antihypertensive agents, belonging to the field of biomedical technology. By analyzing the mRNA sequences of human and rat angiotensin-converting enzyme (ACE), siRNA sequences for silencing ACE protein expression were designed, and unmodified siRNA and siRNA with introduced base modifications were synthesized. Both unmodified and base-modified siRNAs were transfected into human umbilical vein endothelial cells via liposomes. The silencing efficiency of the unmodified siRNA on the ACE gene was 83.42%, while that of the base-modified siRNA was 83.10%. Intravenous injection of both siRNAs into a hypertensive rat model effectively silenced ACE expression, reducing systolic and diastolic blood pressure. The stability of the base-modified siRNA was improved, which could prolong the duration of drug effect and reduce the frequency of administration.

The invention discloses an angiotensin converting enzyme inhibitor tablet and a preparation method thereof, the tablet comprises benazepril hydrochloride as an active component, lactose as an auxiliary material, pregelatinized starch, microcrystalline cellulose, polyvinylpolypyrrolidone, colloidal silicon dioxide and hydrogenated castor oil as a lubricant, and the tablet is prepared by wet granulation and coating treatment. In the preparation process, the comprehensive optimization of the tablet quality is realized by accurately controlling the key steps of raw material sieving, premixing, granulating process, fluidized bed drying, total mixing, tabletting, coating and the like. The benazepril hydrochloride tablet is uniform in component and stable in quality, and provides a more reliable and efficient treatment choice for patients.